Skip to main content
Sign In

University of Colorado Denver

​​​​​​​​​ ​
 

Melanie S. Joy, PharmD, PhD, FCCP, FASN

Assistant Professor, Department of Pharmaceutical Sciences


Mailing Address:

The University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Pharmaceutical Sciences
Mail Stop C238, Room V20-4108
12850 E. Montview Blvd
Aurora, CO 80045

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4410D, E, S

Contact:

Voice - (303) 724-7416 
Lab – (303) 724-7444
Email: Melanie.Joy@ucdenver.edu

Affiliations:

  • Assistant Professor, University of Colorado, School of Medicine, Division of Nephrology
  • Associate Member, University of Colorado, Cancer Center
  • Center for Translational Pharmacokinetics and Pharmacogenomics
  • Co-Founder/Scientific AdvisorKatharos, Inc.
  • Adjunct Associate Professor, University of North Carolina, School of Medicine, Division of Nephrology and Hypertension

Training and Education:

  • PhD (Pharmaceutical Sciences - Molecular Pharmaceutics) University of North Carolina, Chapel Hill, NC
  • PharmD, Duquesne University, Pittsburgh, Pennsylvania
  • BS Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (Magna Cum Laude)

Other Training:

  • Workshop on Phoenix for WinNonlin (v. 6.3), Aurora, CO, 2013
  • Hands-on Experience with Model-Based Drug Development: Incorporating population variability into mechanistic prediction of PK and modeling PK-PD (Simcyp), Princeton, NJ, 2013
  • Workshop on Population Pharmacokinetic Data Analysis Using NONMEM, Buffalo, NY, 2008
  • Workshop on Pharmacokinetic/Pharmacodynamic Modeling, Buffalo, NY, 2008
  • A Short Course in Integrative & Organ Systems Pharmacology 2005

Research/Clinical Interests:

  • In Vivo and In Vitro Drug Metabolism and Transport in Kidney
  • Nephrotoxicity
  • Pharmacokinetics/Pharmacodynamics/Pharmacogenomics
  • Discovery and Translation of Novel Treatment Approaches to Kidney Diseases

Teaching:

  • Graduate: PHSC & TXCL 7310 Fundamentals of Pharmaceutical Sciences
  • Professional: PHSC/TXCL 7452 Introduction to Clinical Pharmacology/PHRD 7801 Principles of Clinical Pharmacology
  • Research Rotations:

Representative Publications:

  • Joy MS, La, M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Brouwer KR, Falk RJ.  Cyclophosphamide and 4-Hydroxycyclophosphamide Pharmacokinetics in Patients with Glomerulonephritis Secondary to Lupus and Small Vessel Vasculitis. Br J Clin Pharmacol 2012;74(3):445-455.
  • Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T.  Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) Phase II Clinical Trial Design. BMC Nephrol. 2011 Feb 10;12(1):8.
  • Joy MS, Boyette T, Hogan SL, Wang J, La MK, Falk RJ, Dooley MA, Stewart P, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady state mycophenolic acid pharmacokinetics in glomerulonephritis.  European Journal of Clinical Pharmacology 2010 June [Epub ahead of print]. Nov;66(11):1119-30.
  • Sam WJ, Joy MSPopulation pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.  Therapeutic Drug Monitoring 2010;32(5):594-605
  • Stanton ML, Joy MS, Frye RF.  Validation and application of a liquid liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.  J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 24. [Epub ahead of print]. 2010 Feb 1;878(3-4):497-501.
  • Joy MS, Frye RF, Stubbert K, Brouwer KRL, Falk RJ, Kharasch ED. Use of Enantiomeric Bupropion and Hydroxybupropion to Assess CYP2B6 Activity in Glomerular Kidney Diseases. J Clin Pharmacol. 2010 Jan 26. [Epub ahead of print] 2010 Jun;50(6):714-20.
  • Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H.  Phase I trial of adalimumab in FSGS: II. Report of the FONT study group.  Am J Kidney Dis. 2009 Nov 20. [Epub ahead of print] 2010 Jan;55(1):50-60.
  • Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in ANCA-associated vasculitis.  Annals of Pharmacotherapy 2009;Jun;43(6):1020-7. Epub 2009 Jun 2.
  • Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA.  CYP2C9 allelic variants and differential pharmacodynamic responses to losartan in patients with chronic kidney disease and proteinuria..  European Journal of Clinical Pharmacology 2009;65(9):947-53.
  • Joy MS, Hilliard T, Hogan SL, Dooley MA, Falk RJ, Smith PC. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy 2009;29(1):7-16.
  • Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H.  Rosiglitazone and N-desmethylrosiglitazone pharmacokinetic are altered in patients with focal segmental glomerulosclerosis (FSGS): I. Report of the novel therapies for resistant FSGS (FONT) study group.  CJASN 2009;4(1):39-47.
  • Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V.  Cytochrome P450 3A5 expression in the kidneys may modulate calcineurin inhibitor nephrotoxicity. Nephrology, Dialysis, Transplantation March 2007;22(7):1963-8.
  • Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF.  Renal expression of P-glycoprotein and nephrotoxicity secondary to calcineurin inhibitors.  Pharmacotherapy 2005;25(6):779-789.
  • Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.  Am J Kidney Dis 2003;42(1):96-107.
  • Joy MS, Cefalu WT, Hogan SL, Nachman P. Long-term glycemic control measurements in diabetic patients receiving hemodialysis.  Am J Kidney Dis 2002;39(2):297-307.
  • Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by CVVH and CVVHD. Antimicrobial Agents and Chemotherapy 2000;44(6):1639-1644.
  • Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by CVVH and CVVVHD. Pharmacotherapy 2000;20(6):635-643.
  • Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by CVVH and CVVHD.  Am J Kidney Dis. 1998;31(6):1019-1027